AzTrials
AzTrials

Patients With Severe Mental IllnessNCT07448675

Cognitive Impairment Characteristics and Biological Mechanisms in Untreated Severe Mental Illness

An observational study of Patients With Severe Mental Illness, run by Tianjin Anding Hospital at 1 site in China.

Enrolling by invitation

Enrolling by invitation. The study team selects and invites participants, usually from an existing group of patients.

Sites and contacts
Official record
Search all trials

Trial summary

Patients with Severe Mental Illness (SMI) frequently exhibit cognitive impairment of varying degrees, involving multiple cognitive domains. These domains include working memory, attention/vigilance, verbal learning and memory, visual learning and memory, reasoning and problem-solving, processing speed, and social… Read more about this study

Who is it for?
Ages 18 to 65 yearsHealthy volunteers can take part
Conditions the study is for
Patients With Severe Mental Illness
How many people
230 participants
Where
1 siteChina
Study dates
7 Feb 2023to 30 Jun 2026
How long will I take part?
12 Weeks
Phase
Observational
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 65 years
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Study population: This study will recruit 150 untreated severe mental illness patients and 80 healthy controls. The 150 subjects, aged 18-65, come from Tianjin Anding Hospital's inpatient/outpatient services and must consent to participate. Untreated patients must meet strict criteria: never taking antipsychotics, or taking them for ≤3 days, or >5 years of illness with <30 lifetime treatment days and no use in the last 5 years (TCM for psychosis excluded). The 80 healthy controls will be matched to patients based on age, gender, education, and residence (urban/rural).

Who may be able to join

  • Aged 18-65 years;
  • Matched to enrolled untreated patients in terms of age, sex, educational attainment, and place of residence (urban or rural).

Who cannot join

  • Psychotic symptoms caused by a general medical condition or substance use;
  • A history of mental retardation (estimated IQ below 70), dementia, head trauma, or brain disease, a history of seizures (epilepsy), or any history of violent or suicidal tendencies;
  • Any factor that prevents the participant from providing informed consent or participating in the study.

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

China1 site
  • Tianjin Anding Hospital

    Tianjin

Other trials in China

About this study

Patients with Severe Mental Illness (SMI) frequently exhibit cognitive impairment of varying degrees, involving multiple cognitive domains. These domains include working memory, attention/vigilance, verbal learning and memory, visual learning and memory, reasoning and problem-solving, processing speed, and social cognition. The severity of this impairment often predicts poorer treatment adherence and serves as a crucial indicator of a patient's capacity for independent living and social reintegration. Research into the mechanisms underlying cognitive impairment offers robust theoretical support for therapeutic interventions in SMI and remains a major focus in psychiatry. However, cognitive impairment is a complex phenomenon; studies focusing on any single cognitive dimension can only reveal partial characteristics and often lack disease specificity. Therefore, there is an urgent need to integrate multiple technical modalities, focusing on a specific biological pathway related to the symptoms of cognitive impairment, to deeply elucidate the process of its onset and to screen for reliable biomarkers. This study will recruit untreated SMI patients and healthy community controls. Upon enrollment, participants will undergo comprehensive assessments including psychiatric symptom evaluation, cognitive function testing, Electroencephalography (EEG), Magnetic Resonance Imaging (MRI), and collection of research blood samples. A follow-up assessment will be conducted at 12 weeks, re-evaluating psychiatric symptoms, cognitive functions, and EEG, while collecting follow-up blood samples and medication records. By integrating these assessment indicators, we aim to identify the potential biological mechanisms underlying cognitive dysfunction in untreated SMI patients, construct a predictive and identification model for cognitive impairment, and explore the concomitant changes in biological markers during the evolution of cognitive impairment through longitudinal follow-up, thus paving the way for prospective targeted interventions.

Keywords
Patients with Severe Mental Illness, cognitive dysfunction, Untreated, longitudinal follow-up, Biological Mechanism
Medical subject headings
Cognitive Dysfunction

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

Study groups in NCT07448675
Study groupRoleWhat they receive
Untreated Severe Mental Illness (SMI) PatientsWe will enroll 150 patients who meet the following inclusion criteria: a current or past episode of a psychotic disorder meeting DSM-5 diagnostic criteria, including Schizophrenia, Schizoaffective Disorder, Acute and Transient Psychotic Disorder, Schizophreniform Disorder, Delusional Disorder, Other Specified or Unspecified Psychotic Disorder, or Bipolar Disorder with psychotic features; age between 18 and 65 years, inclusive; and willingness to participate and sign the informed consent form (ICF); in addition, untreated patients must meet the following specific criteria: no lifetime exposure to antipsychotic medication, or continuous use of antipsychotic medication for a period not exceeding 3 days, or a course of illness exceeding 5 years with no antipsychotic use in the last 5 years and a total lifetime cumulative use of antipsychotic medication of less than 30 days; traditional Chinese medicine used for treating psychotic symptoms will not be counted as antipsychotic medication.
Healthy ControlWe will include 80 healthy controls who meet the following criteria: aged 18-65 years and matched to enrolled untreated patients in terms of age, sex, educational attainment, and place of residence (urban or rural).

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Cognitive Function

    Cognitive function will be assessed using the MATRICS Consensus Cognitive Battery (MATRICS-CN). The following domains will be measured: processing speed, verbal learning, working memory, reasoning and problem-solving, visual learning, and attention/alertness. It possesses excellent psychometric properties, correlates with functional outcomes, and is brief, easy to administer, can be used for home-based assessments, is acceptable to participants, and has domain "robustness." The MATRICS-CN has been translated into Chinese and is available for purchase from PAR, Inc.

    Measured: Baseline, week12

Secondary outcomes (12)
  1. Positive and Negative Symptom Scale (PANSS)

    The psychiatric symptoms of schizophrenia were assessed in all enrolled patients using the Positive and Negative Syndrome Scale (PANSS). The PANSS is a 30-item clinician-rated scale yielding a total score ranging from 30 (least symptomatic) to 210 (symptomatic), where higher scores indicate more severe psychopathology.

    Measured: Baseline, week12

  2. Young Mania Rating Scale (YMRS)

    This is an 11-item clinician-rated scale (scored from 0-4 or 0-8, depending on the items) that assesses the severity of mania and the response to treatment in patients with bipolar disorder. The assessment is based on clinical observation and patient subjective reports regarding symptoms over the past 48 hours.

    Measured: Baseline, week12

  3. Montgomery-Åsberg Depression Rating Scale (MADRS)

    This is a 10-item clinician-rated questionnaire (scored 0-6 per item) that assesses the severity of depressive episodes in patients with affective disorders. The assessment is based on the patient's subjective report of their symptoms over the past week.

    Measured: Baseline, week12

  4. Global Assessment of Functioning (GAF) Scale

    Primarily used to assess the subject's psychological, social, and occupational functioning. The GAF consists of only one dimension: the overall clinical severity level. It is divided into 100 levels (scored from 1-100), where a higher score indicates less severe illness.

    Measured: Baseline, week12

  5. Antisaccade Task Error Rate

    The antisaccade task consists of 4 blocks of 20 trials each. Each trial begins with a central fixation cross. A peripheral visual target appears at 10° or 15° visual angle from fixation, and the fixation cross disappears 200ms after target onset. Participants are instructed to inhibit the reflexive saccade toward the peripheral target and instead generate a saccade to the mirror image location in the opposite visual field. Eye movements are recorded using an eye tracker integrated with the EEG system. The primary outcome is the error rate, calculated as the percentage of trials in which the participant fails to inhibit the reflexive saccade and looks toward the peripheral target rather than the correct mirror location.

    Measured: Baseline, week12

  6. Auditory Paired Stimuli P50 Suppression Ratio

    Auditory paired stimuli are presented binaurally as 150 pairs of broadband auditory stimuli (duration 4s, 75dB). The inter-pair interval averages 9.5s (range 9-10s), and the inter-stimulus interval within each pair is 500ms. EEG is recorded continuously during the task. The P50 evoked potential is identified as the positive deflection occurring 40-80ms post-stimulus at the Cz electrode. The P50 suppression ratio is calculated as the amplitude of the response to the second stimulus (S2) divided by the amplitude of the response to the first stimulus (S1). A lower ratio indicates stronger sensory gating.

    Measured: Baseline, week12

  7. Auditory Oddball P300 Event-Related Potential Amplitude and Latency

    Participants complete an auditory oddball task consisting of 567 standard tones (1000Hz) and 100 target tones (1500Hz) presented in a pseudo-random order, with an inter-stimulus interval of 1300ms. Participants are instructed to press a button upon hearing the target tone. EEG is recorded continuously. The P300 component is measured at the Pz electrode site as the largest positive deflection between 250-500ms post-stimulus. Primary outcomes are: 1) P300 amplitude (µV), defined as the peak voltage relative to a 200ms pre-stimulus baseline; and 2) P300 latency (ms), defined as the time from stimulus onset to the peak amplitude.

    Measured: Baseline, week12

  8. Resting-State EEG Spectral Power in Theta and Alpha Bands

    Resting-state EEG is recorded for 5 minutes with eyes closed using a [具体设备] EEG system with electrodes placed according to the 10-20 system. Data are segmented into 2-second epochs and artifacts are removed via independent component analysis. Power spectral density (µV²/Hz) is calculated using fast Fourier transform. The primary outcomes are mean power in the theta band (4-8 Hz) and alpha band (8-13 Hz) at frontal and parietal electrode sites.

    Measured: Baseline, week12

  9. Gray Matter Volume from Structural MRI

    High-resolution T1-weighted structural MRI scans are acquired using a [3T Siemens Prisma] MRI scanner. Images are preprocessed using voxel-based morphometry (VBM) with SPM12 software. Gray matter is segmented from white matter and cerebrospinal fluid. The primary outcome is the regional gray matter volume (mm³) in regions of interest, normalized for total intracranial volume.

    Measured: Baseline, week12

  10. Fractional Anisotropy from Diffusion Tensor Imaging (DTI)

    Diffusion tensor imaging (DTI) data are acquired using a single-shot echo-planar imaging sequence with 30 diffusion directions (b-value = 1000 s/mm²) and one non-diffusion-weighted image (b=0). Data are preprocessed for eddy current and motion correction using FSL software. Fractional anisotropy (FA) maps are calculated, representing the directionality of water diffusion in white matter tracts. The primary outcome is the mean FA value in major white matter tracts (e.g., corpus callosum, cingulum bundle), with FA values ranging from 0 (isotropic diffusion) to 1 (completely anisotropic diffusion).

    Measured: Baseline, week12

  11. Amplitude of Low-Frequency Fluctuations (ALFF) from Resting-State fMRI

    Resting-state functional MRI (fMRI) data are acquired using a gradient-echo echo-planar imaging sequence while participants are instructed to remain awake with eyes closed. Data are preprocessed including slice-timing correction, head motion correction, and spatial normalization to standard MNI space. The amplitude of low-frequency fluctuations (ALFF) is calculated as the square root of the power spectrum in the low-frequency range (0.01-0.08 Hz). The primary outcome is the mean ALFF value in predefined regions of interest, reflecting the intensity of spontaneous brain activity.

    Measured: Baseline, week12

  12. Resting-State Functional Connectivity (Seed-Based)

    Using the same resting-state fMRI data described above, functional connectivity is assessed using a seed-based correlation approach. The mean time series is extracted from a seed region of interest (e.g., posterior cingulate cortex for default mode network). Pearson's correlation coefficients are calculated between the seed time series and all other voxels in the brain. Correlation coefficients are then transformed to Fisher's z-scores for normalization. The primary outcome is the strength of functional connectivity (Fisher's z) between the seed region and target brain regions.

    Measured: Baseline, week12

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted4 Mar 2026
  2. Study start7 Feb 2023
  3. Primary completion1 Jun 2026 (estimated)
  4. Study completion30 Jun 2026 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
230 participants (estimated)
Target duration
12 Weeks
IDs, dates and publications
ClinicalTrials.gov ID
NCT07448675
Sponsor's protocol ID
SMI-UT
Status last verified
Jan 2026
First submitted
19 Jan 2026
Last updated
4 Mar 2026
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

An observational study of Patients With Severe Mental Illness, run by Tianjin Anding Hospital at 1 site in China.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: enrolling by invitation, as of the sponsor's last update on 4 Mar 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Cognitive Function (time frame: Baseline, week12). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 4 Mar 2026; AzTrials last refreshed its copy on 7 Nov 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in